ReviewBioMed research international2015
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An original study assessing biomarker success rate in breast cancer recurrence biomarker research.BMC medicine · 2024Pooled it
- Enzyme-Linked Cycloaddition Assay (ELCA) for Rapid, Ultra-Sensitive Monitoring of Secreted Sialoglycoproteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Role of glycosylated small noncoding RNAs in tumor: mechanism, function and clinical significance.Glycoconjugate journal · 2026Review
- Predictive ability of novel glycovariant biomarkers of CA125 and CA15-3 up to three years prior to ovarian cancer diagnosis: a population-based case-control study.Journal of ovarian research · 2026Article
- Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026Review
- Glycan and glycoprotein signatures in tumor-induced liver alterations in a murine breast cancer model.Molecular genetics and genomics : MGG · 2026Article
- Gangliosides in molecular interactions and cell regulation.The Journal of biological chemistry · 2026Review
- Hematologic Glyco-Signatures: Emerging Blood-Based Sugar Codes Linked to Hyper-Aggressive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Review
- Analytical Techniques as Indicators of Biomarkers in Proteomics Cancer Diagnosis.Anti-cancer agents in medicinal chemistry · 2026Review
- Altered Cell SurfaceJournal of proteome research · 2025Article
- Serum immunoglobulin G glycosylation profiling in breast cancer using a 56-lectin microarray and subtype-specific patterns.Gland surgery · 2025Article
- Fabrication of serum-based SERS-tailored 3D structures for thyroid cancer diagnosis.Scientific reports · 2025Article
- Glycoproteomics of Gastrointestinal Cancers and Its Use in Clinical Diagnostics.Journal of proteome research · 2025Review
- Anti-CHI3L1 antibody suppresses colon cancer growth through downregulation of VEGFA and NAMPT expression.Archives of pharmacal research · 2025Article
- In-depth plasma N-glycoproteome profiling using narrow-window data-independent acquisition on the Orbitrap Astral mass spectrometer.Nature communications · 2025Article
- Interfacial cfDNA Enrichment and Amplification with On-Chip Thermoplasmonics for Highly Sensitive Cancerous Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Integrating the analysis of human biopsies using post-translational modifications proteomics.Protein science : a publication of the Protein Society · 2024Review
- Decoding the glycoproteome: a new frontier for biomarker discovery in cancer.Journal of hematology & oncology · 2024Review
- Robust Glycoproteomics Platform Reveals a Tetra-Antennary Site-Specific Glycan Capping with Sialyl-Lewis Antigen for Early Detection of Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Probing Blood Plasma Protein Glycosylation with Infrared Spectroscopy.Analytical chemistry · 2024Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the second most common cause of death in developed countries with approximately 14 million newly diagnosed individuals and over 6 million cancer-related deaths in 2012. Many cancers are discovered at a more advanced stage but better survival rates are correlated with earlier detection. Current clinically approved cancer biomarkers are most effective when applied to patients with widespread cancer. Single biomarkers with satisfactory sensitivity and specificity have not been identified for the most common cancers and some biomarkers are ineffective for the detection of early stage cancers. Thus, novel biomarkers with better diagnostic and prognostic performance are required. Aberrant protein glycosylation is well known hallmark of cancer and represents a promising source of potential biomarkers. Glycoproteins enter circulation from tissues or blood cells through active secretion or leakage and patient serum is an attractive option as a source for biomarkers from a clinical and diagnostic perspective. A plethora of technical approaches have been developed to address the challenges of glycosylation structure detection and determination. This review summarises currently utilised glycoprotein biomarkers and novel glycosylation-based biomarkers from the serum glycoproteome under investigation as cancer diagnostics and for monitoring and prognostics and includes details of recent high throughput and other emerging glycoanalytical techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.